Evidence map›Paper›PMID 26028974›Full record

ReviewTherapeutics and clinical risk management2015

Optimal management of constipation associated with irritable bowel syndrome.

Manuele Furnari, Nicola de Bortoli, Irene Martinucci, Giorgia Bodini, Matteo Revelli, Elisa Marabotto, Alessandro Moscatelli, Lorenzo Del Nero, Edoardo Savarino, Edoardo G Giannini and 1 more

Open access · goldAbstract readReview
In one paragraph

Review in Therapeutics and clinical risk management, 2015. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 4 papers.

0numbers the graph read from it
0cells of the map it votes in
4citing papers in PubMed
1.4field-weighted citation impact, top 20% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

4 citing papers in PubMed, 15 citations in OpenAlex.

  1. Do MicroRNAs Modulate Visceral Pain?BioMed research international · 2018
    Review
  2. Dietary fiber in irritable bowel syndrome (Review).International journal of molecular medicine · 2017
    Article
  3. Review
  4. Article
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

11 authors at 3 institutions in 1 country.

Manuele FurnariDivision of Gastroenterology, Department of Internal Medicine, University of Genoa, Genoa, Italy.
Nicola de BortoliDivision of Gastroenterology, Department of Translational Research and New Technology in Medicine and Surgery, University of Pisa, Pisa, Italy.
Irene MartinucciDivision of Gastroenterology, Department of Translational Research and New Technology in Medicine and Surgery, University of Pisa, Pisa, Italy.
Giorgia BodiniDivision of Gastroenterology, Department of Internal Medicine, University of Genoa, Genoa, Italy.
Matteo RevelliDepartment of Radiology, San Bartolomeo Hospital, Sarzana, Italy.
Elisa MarabottoDivision of Gastroenterology, Department of Internal Medicine, University of Genoa, Genoa, Italy.
Alessandro MoscatelliDivision of Gastroenterology, Department of Internal Medicine, University of Genoa, Genoa, Italy.
Lorenzo Del NeroDivision of Gastroenterology, Department of Internal Medicine, University of Genoa, Genoa, Italy.
Edoardo SavarinoDivision of Gastroenterology, Department of Surgery, Oncology, and Gastroenterology, University of Padua, Padua, Italy.
Edoardo G GianniniDivision of Gastroenterology, Department of Internal Medicine, University of Genoa, Genoa, Italy.
Vincenzo SavarinoDivision of Gastroenterology, Department of Internal Medicine, University of Genoa, Genoa, Italy.
University of Genoa · ITUniversity of Pisa · ITUniversity of Padua · IT

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

Irritable bowel syndrome (IBS) is a common chronic functional disorder of the gastrointestinal tract, meanly characterized by recurrent abdominal pain or discomfort and altered bowel habit. It is a complex disorder involving biological, environmental, and psychosocial factors. The diagnosis is achieved according to the Rome III criteria provided that organic causes have been excluded. Although IBS does not constitute a life-threatening condition, it has a remarkable prevalence and profoundly reduces the quality of life with burdening socioeconomic costs. One of the principal concerns about IBS is the lack of effective therapeutic options. Up to 40% of patients are not satisfied with any available medications, especially those suffering from chronic constipation. A correct management of IBS with constipation should evolve through a global approach focused on the patient, starting with careful history taking in order to assess the presence of organic diseases that might trigger the disorder. Therefore, the second step is to examine lifestyle, dietary habits, and psychological status. On these bases, a step-up management of disease is recommended: from fiber and bulking agents, to osmotic laxative drugs, to new molecules like lubiprostone and linaclotide. Although new promising tools for relief of bowel-movement-related symptoms are being discovered, a dedicated doctor-patient relationship still seems to be the key for success.

Indexed as

functional gastrointestinal disordersIBSlaxatives

Identifiers

PMID26028974
PMCPMC4425337
OpenAlexW1521398752

What OpenQuestion holds

Textmetadata
LicenceCC BY-NC
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.